Cargando…

Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease

The response rate to obeticholic acid (OCA), a potential therapeutic agent for non-alcoholic fatty liver disease, is limited. This study demonstrated that upregulation of the alternative bile acid synthesis pathway increases the OCA treatment response rate. The hepatic transcriptome and bile acid me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Seung Min, Jun, Dae Won, Yoon, Eileen Laurel, Oh, Ju Hee, Roh, Yoon Jin, Lee, Eun Jeoung, Shin, Ji-Hee, Nam, Young-Do, Kim, Hyun Sung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463927/ https://www.ncbi.nlm.nih.gov/pubmed/37626369 http://dx.doi.org/10.1186/s13062-023-00407-4

Ejemplares similares

Regulation of Hepatocyte Nuclear Factor 4α Attenuated Lipotoxicity but Increased Bile Acid Toxicity in Non-Alcoholic Fatty Liver Disease
por: Roh, Yoon Jin, et al.
Publicado: (2022)

ALS-L1023 from Melissa officinalis Alleviates Liver Fibrosis in a Non-Alcoholic Fatty Liver Disease Model
por: Lee, Eun Jeoung, et al.
Publicado: (2022)

Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial
por: Oh, Ju Hee, et al.
Publicado: (2022)

Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
por: Yoon, Eileen Laurel, et al.
Publicado: (2023)

Reappraisal of fibrosis-4 index and non-alcoholic fatty liver disease fibrosis score for advanced fibrosis in average-risk population
por: Park, Huiyul, et al.
Publicado: (2022)

A survey on the awareness, current management, and barriers for non-alcoholic fatty liver disease among the general Korean population
por: Lee, Jun-Hyuk, et al.
Publicado: (2023)

Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways
por: Lee, Seung Min, et al.
Publicado: (2022)

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016)

Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review
por: Ahmed, Nabeel R, et al.
Publicado: (2022)

Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
por: Abenavoli, Ludovico, et al.
Publicado: (2018)

The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease
por: Zhang, Dan-Ying, et al.
Publicado: (2019)

Association of non-alcoholic fatty liver disease with renal stone disease detected on computed tomography
por: Nam, In Chul, et al.
Publicado: (2016)

Obeticholic acid for primary biliary cholangitis
Publicado: (2020)

Obeticholic Acid for Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)

Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice
por: Liu, Szu-Yu, et al.
Publicado: (2022)

Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status
por: Roy, Partho Pratik, et al.
Publicado: (2022)

Clarification of Obeticholic Acid Dosing: Response to “Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation” by Quigley et al.
por: Feng, Cynthia
Publicado: (2018)

Alcohol Use during Pregnancy and Related Risk Factors in Korea
por: Lee, So Hee, et al.
Publicado: (2010)

Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver
por: Park, Huiyul, et al.
Publicado: (2021)

Obeticholic acid attenuates human immunodeficiency virus/alcohol metabolism-induced pro-fibrotic activation in liver cells
por: New-Aaron, Moses, et al.
Publicado: (2020)

Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease”
por: Yoon, Eileen L., et al.
Publicado: (2023)

Risk factors in nonalcoholic fatty liver disease
por: Ko, Eunji, et al.
Publicado: (2023)

Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice
por: Lin, Chuangzhen, et al.
Publicado: (2022)

OptNCMiner: a deep learning approach for the discovery of natural compounds modulating disease-specific multi-targets
por: Shin, Seo Hyun, et al.
Publicado: (2022)

Reproducibility and validity of semi-quantitative food frequency questionnaire measuring dietary trans-fatty acids intake among Korean adults
por: Joh, Hee-Kyung, et al.
Publicado: (2015)

Waiting for Multi-Stakeholders̕ Consensus Position Statement on New Nonalcoholic Fatty Liver Disease Nomenclature
por: Yoon, Eileen L., et al.
Publicado: (2022)

Mismatched effects of receptor interacting protein kinase-3 on hepatic steatosis and inflammation in non-alcoholic fatty liver disease
por: Saeed, Waqar Khalid, et al.
Publicado: (2018)

Co-administration of obeticholic acid and simvastatin protects against high-fat diet-induced non-alcoholic steatohepatitis in mice
por: Li, Wen-Cong, et al.
Publicado: (2021)

Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice
por: Li, Shengjie, et al.
Publicado: (2022)

Peripheral blood mononuclear cell mitochondrial copy number and adenosine triphosphate inhibition test in NAFLD
por: Lee, A-Hyeon, et al.
Publicado: (2022)

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
por: Di Matteo, S., et al.
Publicado: (2019)

Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage
por: Edwards, JE, et al.
Publicado: (2016)

New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
por: Jhaveri, Manan A, et al.
Publicado: (2017)

Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
por: Zhou, Jiyu, et al.
Publicado: (2019)

Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis
por: Roberts, Surain B., et al.
Publicado: (2020)

Real-world experience with obeticholic acid in patients with primary biliary cholangitis
por: D’Amato, Daphne, et al.
Publicado: (2021)

Obeticholic Acid Decreases Intestinal Content of Enterococcus in Rats With Cirrhosis and Ascites
por: Yan, Kathleen, et al.
Publicado: (2021)

Obeticholic acid ameliorates obesity and hepatic steatosis by activating brown fat
por: Zhang, Hanlin, et al.
Publicado: (2021)

Sarcopenic Obesity, the Possible Culprit for Nonalcoholic Fatty Liver Disease or Fibrosis
por: Kang, Seong Hee, et al.
Publicado: (2023)

Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea
por: Jeong, Eun Haeng, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gog4u4014k04e3boqta52orkqv